Efficacy of oral JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis
收藏官方服务：
资源简介：
Supplemental materials
补充材料
应用场景：
创建时间：
2024-01-31
相关数据集
Table8_Anti-inflammatory and immunomodulatory effects of polysaccharide extracted from Wuguchong (maggot) on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice.XLSX
Atopic dermatitis (AD) is an inflammatory, heterogeneous, chronic skin disorder characterized by recurrent eczematous lesions and intense pruritus, and the pathophysiology mechanism of AD is known for
NIAID Data Ecosystem180
Silverberg et al. 2026. JAAD. 487-GEP SUPPLEMENTAL MATERIAL
Supplemental material for Silverberg et al. JAAD. The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospec
NIAID Data Ecosystem50
Table_2_The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis.docx
BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD). Howeve
NIAID Data Ecosystem30
Oral JAK Inhibitors in the Management of Nail Psoriasis: An Evidence Based Review
Nail psoriasis is a manifestation of psoriasis localized to the nails, often presenting with pitting, onycholysis, and subungual hyperkeratosis. Currently, there are no FDA approved treatments specifi
Mendeley Data70
Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms. Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms
Comprehensive profiing of clinical JAK inhibitors in myeloproliferative neoplasms Overall design: HEL cells were treated in duplicate for 4 hour or 48 hours with DMSO control or 500nM of JAK inhibitor
NIAID Data Ecosystem40
